Roxithromycin: Advanced Macrolide Antibiotic for Respiratory and Skin Infections
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.99 | $59.27 (0%) | 🛒 Add to cart |
| 90 | $0.90 | $88.91 $81.37 (8%) | 🛒 Add to cart |
| 120 | $0.85 | $118.54 $102.47 (14%) | 🛒 Add to cart |
| 180 | $0.81 | $177.81 $146.67 (18%) | 🛒 Add to cart |
| 270 | $0.79 | $266.72 $211.97 (21%) | 🛒 Add to cart |
| 360 | $0.78
Best per pill | $355.62 $279.28 (21%) | 🛒 Add to cart |
Synonyms
| |||
Roxithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin, designed to offer enhanced pharmacokinetic properties and a broad spectrum of antibacterial activity. It is particularly effective against Gram-positive bacteria, some Gram-negative organisms, and atypical pathogens, making it a versatile choice for treating community-acquired infections. Its improved acid stability and tissue penetration ensure reliable efficacy with a convenient once- or twice-daily dosing regimen, supporting patient adherence and therapeutic success.
Features
- Active Ingredient: Roxithromycin 150 mg or 300 mg per tablet
- Drug Class: Macrolide antibiotic
- Mechanism of Action: Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis
- Spectrum: Effective against Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae
- Bioavailability: Approximately 50%, with peak plasma concentrations reached within 2 hours post-administration
- Half-Life: 12 hours, allowing for less frequent dosing
- Formulation: Film-coated tablets for oral administration
- Prescription Status: Prescription-only medication
Benefits
- High Efficacy: Demonstrates strong bactericidal activity against common respiratory and skin pathogens, reducing infection duration and severity.
- Convenient Dosing: Extended half-life supports once- or twice-daily administration, improving compliance, especially in outpatient settings.
- Good Tissue Penetration: Achieves effective concentrations in lungs, skin, and tonsils, targeting infection sites directly.
- Favorable Safety Profile: Generally well-tolerated, with a lower incidence of gastrointestinal side effects compared to older macrolides.
- Broad-Spectrum Coverage: Active against atypical bacteria such as Mycoplasma and Chlamydia, often implicated in community-acquired pneumonia.
- Acid Stability: Less susceptible to degradation in gastric acid, ensuring consistent absorption and reliable pharmacokinetics.
Common use
Roxithromycin is indicated for the treatment of mild to moderate infections caused by susceptible microorganisms. Common clinical applications include:
- Upper and lower respiratory tract infections, such as pharyngitis, tonsillitis, acute bronchitis, community-acquired pneumonia, and acute sinusitis.
- Skin and soft tissue infections, including impetigo, erysipelas, and secondary infected dermatoses.
- Genitourinary infections caused by Chlamydia trachomatis (e.g., non-gonococcal urethritis and cervicitis).
- Dental infections, such as periodontitis and pericoronitis, when caused by susceptible organisms.
Dosage and direction
The standard adult dosage is 300 mg daily, administered either as a single dose or in two divided doses of 150 mg each. For severe infections, the dose may be increased to 300 mg twice daily. Treatment duration typically ranges from 5 to 10 days, depending on the type and severity of the infection. In patients with renal impairment (creatinine clearance <30 mL/min), dosage adjustment may be necessary; however, due to primarily hepatic metabolism, significant modification is rarely required. Tablets should be swallowed whole with a glass of water, preferably before meals to optimize absorption.
Precautions
- Use with caution in patients with hepatic impairment, as roxithromycin is metabolized in the liver. Periodic liver function tests are advisable during prolonged therapy.
- May prolong the QT interval; avoid use in patients with known QT prolongation, electrolyte imbalances, or those taking other QT-prolonging drugs.
- Not recommended during pregnancy unless clearly needed; animal studies show no direct teratogenicity, but human data are limited.
- Exercise caution in breastfeeding women; small amounts are excreted in breast milk.
- Superinfections, including fungal or bacterial overgrowth, may occur with prolonged use.
- Inform patients that roxithromycin may cause dizziness or visual disturbances; advise against driving or operating machinery if affected.
Contraindications
- Hypersensitivity to roxithromycin, other macrolide antibiotics, or any component of the formulation.
- Concurrent use with ergot derivatives, cisapride, pimozide, or terfenadine due to risk of serious cardiac events.
- History of hepatitis or jaundice associated with previous macrolide use.
- Severe hepatic impairment without close monitoring.
Possible side effect
Most side effects are mild to moderate and transient. Common adverse reactions include:
- Gastrointestinal: Nausea, abdominal pain, diarrhea, vomiting, dyspepsia.
- Dermatological: Rash, pruritus, urticaria.
- Neurological: Headache, dizziness.
- Hepatic: Transient elevations in liver enzymes.
- Other: Taste perversion, oral candidiasis.
Rare but serious side effects may include:
- Hepatotoxicity, including hepatitis and cholestatic jaundice.
- QT prolongation and ventricular arrhythmias.
- Severe skin reactions such as Stevens-Johnson syndrome.
- Clostridium difficile-associated diarrhea.
Drug interaction
Roxithromycin is a substrate and inhibitor of CYP3A4, leading to several clinically significant interactions:
- Contraindicated combinations: Ergot alkaloids (e.g., ergotamine), cisapride, pimozide, terfenadine—increased risk of cardiotoxicity.
- Increased concentrations of: Theophylline, digoxin, warfarin, cyclosporine, midazolam, simvastatin—monitor levels and adjust doses as needed.
- Reduced efficacy of: Oral contraceptives; advise alternative contraception during treatment.
- Other macrolides or CYP3A4 inhibitors may increase roxithromycin exposure.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms of overdose may include severe nausea, vomiting, diarrhea, and transient hearing loss. Management is supportive; gastric lavage may be considered if ingestion was recent. There is no specific antidote. Hemodialysis is not effective due to high protein binding. Monitor cardiac function (ECG) and electrolyte levels in cases of significant overdose.
Storage
Store at room temperature (15–30°C), in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosage recommendations. Do not self-medicate. The efficacy and safety profile may vary based on individual patient factors and local prescribing guidelines.
Reviews
Roxithromycin is generally well-regarded in clinical practice for its balance of efficacy, tolerability, and convenience. In studies, it demonstrates comparable effectiveness to other macrolides like clarithromycin and azithromycin for respiratory infections, with a lower incidence of gastrointestinal adverse effects. Some clinicians note its utility in penicillin-allergic patients. However, its spectrum does not cover all Gram-negative bacteria, and resistance patterns should be considered based on regional epidemiology. Patient reviews often highlight the ease of once-daily dosing and minimal disruption to daily activities.